Marta Jimenez Fernandez

Marta Jimenez Fernandez

Auto-generated profile, based on publicly available information

Marta Jimenez Fernandez

Thoracic Surgery Departmente, Getafe University Hospital, Madrid, Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2020 in Multidisciplinary Respiratory Medicine
Verified
Journal Article
Open access
PDF file
CPCarolina Panadero
Carolina Panadero
AAAraceli Abad-Fernández
Araceli Abad-Fernández
MRMª Teresa Rio-Ramírez
Mª Teresa Rio-Ramírez
CGCarmen Maria Acosta Gutiérrez
Carmen Maria Acosta Gutiérrez
MCMariara Calderón-Alcalá
Mariara Calderón-Alcalá
AAAndres Jose Alcaraz
Andres Jose Alcaraz
Background: High-flow nasal cannula oxygen therapy (HFNC) has been shown to be a useful therapy in the treatment of patients with Acute Respiratory Distress Syndrome (ARDS), but its efficacy is still unknown in patients with COVID-19. Our objective is to describe its utility as therapy for the treatment of ARDS caused by SARS-CoV-2. Methods: A retrospective, observational study was performed at a single centre, evaluating patients with ARDS secondary to COVID-19 treated with HFNC. The main outcome was the intubation rate at day 30, which defined failure of therapy. We also analysed the role of the ROX index to predict the need for intubation.Results: In the study period, 196 patients with bilateral pneumonia were admitted to our pulmonology unit, 40 of whom were treated with HFNC due to the presence of ARDS. The intubation rate at day 30 was 52.5%, and overall mortality was 22.5%. After initiating HFNC, the SpO2/FiO2 ratio was significantly better in the group that did not require intubation (113.4±6.6 vs 93.7±6.7, p=0.020), as was the ROX index (5.0±1.6 vs 4.0±1.0, p=0.018). A ROX index less than 4.94 measured 2 to 6 h after the start of therapy was associated with increased risk of intubation (HR 4.03 [95% CI 1.18 – 13.7]; p=0.026).Conclusion: High-flow therapy is a useful treatment in ARDS in order to avoid intubation or as a bridge therapy, and no increased mortality was observed secondary to the delay in intubation. After initiating HFNC, a ROX index below 4.94 predicts the need for intubation.

28 November 2024 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
FMFrancisco Javier Teigell Muñoz
Francisco Javier Teigell Muñoz
ATAna Sánchez-De Torre
Ana Sánchez-De Torre
MJMarta Jiménez-Fernández
Marta Jiménez-Fernández
LGLorenzo Zuñiga Gómez
Lorenzo Zuñiga Gómez
MGMaría Mateos González
María Mateos González
JAJesús Fortún Abete
Jesús Fortún Abete